Antifibrinolytic Agents in Cardiac and Noncardiac Surgery: A Comprehensive Overview and Update

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 31, Issue 6, 2017, Pages 2183-2205

  Gerstein, Neal S ^a   Brierley, Janet K ^a   Windsor, Jimmy ^a   Panikkath, Pramod V ^a   Ram, Harish ^a   Gelfenbeyn, Kirill M ^a   Jinkins, Lindsay J ^a   Nguyen, Liem C ^b   Gerstein, Wendy H ^c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA Medical Center   (United States)

Author keywords

aminocaproic acid; antifibrinolytic; antifibrinolytic agents; aprotinin; blood transfusion; cardiac surgical procedures; cardiopulmonary bypass; coagulation; multiple trauma; postoperative hemorrhage; serine proteinase inhibitors; surgical bleeding; tranexamic acid

Indexed keywords

AMINOCAPROIC ACID; APROTININ; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ANAPHYLAXIS; BILIARY TRACT SURGERY; BLEEDING; COGNITIVE DEFECT; CRANIOFACIAL SURGERY; CRANIOFACIAL SYNOSTOSIS; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG COST; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; HEART SURGERY; HEPATOBILIARY DISEASE; HUMAN; HYPERKALEMIA; INJURY; INTRACARDIAC THROMBOSIS; KIDNEY DYSFUNCTION; KIDNEY INJURY; KIDNEY NECROSIS; LIVER SURGERY; LUNG EMBOLISM; MYOPATHY; OBSTETRIC OPERATION; OCCLUSIVE CEREBROVASCULAR DISEASE; OFF PUMP CORONARY SURGERY; ORTHOPEDIC SURGERY; PEDIATRIC SURGERY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SCOLIOSIS; SEIZURE; SUBARACHNOID HEMORRHAGE; THROMBOEMBOLISM; BLOOD; CHEMICALLY INDUCED; OPERATIVE BLOOD LOSS; POSTOPERATIVE COMPLICATION; TRENDS;

ANTIFIBRINOLYTIC AGENTS; BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; HUMANS; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS;

EID: 85018325532     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2017.02.029     Document Type: Review

References (230)

1. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris, V.A., Brown, J.R., et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 91 (2011), 944–982.
2. Tengborn, L., Blomback, M., Berntorp, E., Tranexamic acid—an old drug still going strong and making a revival. Thromb Res 135 (2015), 231–242.
3. World Health Organization. WHO model list of essential medicines. Available at: http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed November 5, 2016.
4. Roberts, I., Prieto-Merino, D., Applying results from clinical trials: Tranexamic acid in trauma patients. J Intensive Care, 2, 2014, 56.
5. Cole, E., Davenport, R., Willett, K., et al. Tranexamic acid use in severely injured civilian patients and the effects on outcomes: A prospective cohort study. Ann Surg 261 (2015), 390–394.
6. World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. Available at: http://apps.who.int/iris/bitstream/10665/75411/1/9789241548502_eng.pdf. Accessed January 14, 2017.
7. Novikova, N., Hofmeyr, G.J., Cluver, C., Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev, 2015, CD:007872.
8. Dalmau, A., Sabate, A., Acosta, F., et al. Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 91 (2000), 29–34.
9. Porte, R.J., Molenaar, I.Q., Begliomini, B., et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: A multicentre randomised double-blind study. EMSALT Study Group. Lancet 355 (2000), 1303–1309.
10. Rasouli, M.R., Parvizi, J., Tranexamic acid in total joint arthroplasty: Efficacy and safety. Arch Bone Jt Surg 3 (2015), 1–2.
11. Zehtabchi, S., Abdel Baki, S.G., Falzon, L., et al. Tranexamic acid for traumatic brain injury: A systematic review and meta-analysis. Am J Emerg Med 32 (2014), 1503–1509.
12. Opoku-Anane, J., Vargas, M.V., Moawad, G., et al. Use of intravenous tranexamic acid during myomectomy: A randomized double-blind placebo controlled trial. J Minim Invasive Gynecol, 22, 2015, S197.
13. Crescenti, A., Borghi, G., Bignami, E., et al. Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: Double blind, randomised, placebo controlled trial. BMJ, 343, 2011, d5701.
14. Chee, Y.E., Liu, S.E., Irwin, M.G., Management of bleeding in vascular surgery. Br J Anaesth 117:Suppl 2 (2016), ii85–ii94.
15. Urban, D., Dehaeck, R., Lorenzetti, D., et al. Safety and efficacy of tranexamic acid in bleeding paediatric trauma patients: A systematic review protocol. BMJ Open, 6, 2016, e012947.
16. Nilsson, I.M., Sjoerdsma, A., Waldenstrom, J., Antifibrinolytic activity and metabolism of 6-aminocaproic acid in man. Lancet 1 (1960), 1322–1326.
17. Deysine, M., Cliffton, E.E., Mechanism of action of epsilon aminocaproic acid in the control of hemorrhage. Ann N Y Acad Sci 115 (1964), 291–297.
18. Sack, E., Spaet, T.H., Gentile, R.L., et al. Reduction of postprostatectomy bleeding by episilon-aminocaproic acid. N Engl J Med 266 (1962), 541–543.
19. Al-Horani, R.A., Desai, U.R., Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders. Med Res Rev 34 (2014), 1168–1216.
20. RxList. Amicar (Aminocaproic Acid Dug Information): Clinical Pharmacology. Available at: http://www.rxlist.com/amicar-drug/clinical-pharmacology.htm. Accessed March 8, 2017.
21. Tovi, D., The use of antifibrinolytic drugs to prevent early recurrent aneurysmal subarachnoid haemorrhage. Acta Neurol Scand 49 (1973), 163–175.
22. Fish, S.S., Pancorbo, S., Berkseth, R., Pharmacokinetics of epsilon-aminocaproic acid during peritoneal dialysis. J Neurosurg 54 (1981), 736–739.
23. Stricker, P.A., Zuppa, A.F., Fiadjoe, J.E., et al. Population pharmacokinetics of epsilon-aminocaproic acid in infants undergoing craniofacial reconstruction surgery. Br J Anaesth 110 (2013), 788–799.
24. Eaton, M.P., Alfieris, G.M., Sweeney, D.M., et al. Pharmacokinetics of epsilon-aminocaproic acid in neonates undergoing cardiac surgery with cardiopulmonary bypass. Anesthesiology 122 (2015), 1002–1009.
25. Mangano, D.T., Tudor, I.C., Dietzel, C., et al. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006), 353–365.
26. DelRossi, A.J., Cernaianu, A.C., Botros, S., et al. Prophylactic treatment of postperfusion bleeding using EACA. Chest 96 (1989), 27–30.
27. Brown, J.R., Birkmeyer, N.J., O'Connor, G.T., Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 115 (2007), 2801–2813.
28. Fergusson, D.A., Hebert, P.C., Mazer, C.D., et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358 (2008), 2319–2331.
29. Raghunathan, K., Connelly, N.R., Kanter, G.J., epsilon-Aminocaproic acid and clinical value in cardiac anesthesia. J Cardiothorac Vasc Anesth 25 (2011), 16–19.
30. Henry, D.A., Carless, P.A., Moxey, A.J., et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev, 2011, CD:001886.
31. Makhija, N., Sarupria, A., Kumar Choudhary, S., et al. Comparison of epsilon aminocaproic acid and tranexamic acid in thoracic aortic surgery: Clinical efficacy and safety. J Cardiothorac Vasc Anesth 27 (2013), 1201–1207.
32. Falana, O., Patel, G., Efficacy and safety of tranexamic acid versus aminocaproic acid in cardiovascular surgery. Ann Pharmacother 48 (2014), 1563–1569.
33. American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: An updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management. Anesthesiology 122 (2015), 241–275.
34. Biglioli, P., Cannata, A., Alamanni, F., et al. Biological effects of off-pump vs. on-pump coronary artery surgery: Focus on inflammation, hemostasis and oxidative stress. Eur J Cardiothorac Surg 24 (2003), 260–269.
35. Vallely, M.P., Bannon, P.G., Bayfield, M.S., et al. Quantitative and temporal differences in coagulation, fibrinolysis and platelet activation after on-pump and off-pump coronary artery bypass surgery. Heart Lung Circ 18 (2009), 123–130.
36. Casati, V., Gerli, C., Franco, A., et al. Activation of coagulation and fibrinolysis during coronary surgery: On-pump versus off-pump techniques. Anesthesiology 95 (2001), 1103–1109.
37. Cheng, D.C., Bainbridge, D., Martin, J.E., et al. Does off-pump coronary artery bypass reduce mortality, morbidity, and resource utilization when compared with conventional coronary artery bypass? A meta-analysis of randomized trials. Anesthesiology 102 (2005), 188–203.
38. Martin, J., Cheng, D., Tranexamic acid for routine use in off-pump coronary artery bypass surgery: Evidence base “fait accompli” or more research needed?. Anesth Analg 115 (2012), 227–230.
39. Churchill, J.L., Puca, K.E., Meyer, E., et al. Comparing epsilon-aminocaproic acid and tranexamic acid in reducing postoperative transfusions in total knee arthroplasty. J Knee Surg, 2016 Oct 3 [E-pub ahead of print].
40. Huang, F., Wu, Y., Yin, Z., et al. A systematic review and meta-analysis of the use of antifibrinolytic agents in total hip arthroplasty. Hip Int 25 (2015), 502–509.
41. Camarasa, M.A., Olle, G., Serra-Prat, M., et al. Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: A randomized clinical trial. Br J Anaesth 96 (2006), 576–582.
42. Churchill, J.L., Toney, V.A., Truchan, S., et al. Using aminocaproic acid to reduce blood loss after primary unilateral total knee arthroplasty. Am J Orthop 45 (2016), E245–E248.
43. Kagoma, Y.K., Crowther, M.A., Douketis, J., et al. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: A systematic review of randomized trials. Thrombosis Research 123 (2009), 687–696.
44. Ray, M., Hatcher, S., Whitehouse, S.L., et al. Aprotinin and epsilon aminocaproic acid are effective in reducing blood loss after primary total hip arthroplasty—a prospective randomized double-blind placebo-controlled study. J Thromb Haemost 3 (2005), 1421–1427.
45. Peters, A., Verma, K., Slobodyanyuk, K., et al. Antifibrinolytics reduce blood loss in adult spinal deformity surgery: A prospective, randomized controlled trial. Spine 40 (2015), E443–E449.
46. Elgafy, H., Bransford, R.J., McGuire, R.A., et al. Blood loss in major spine surgery: Are there effective measures to decrease massive hemorrhage in major spine fusion surgery?. Spine 35 (2010), S47–S56.
47. Willner, D., Spennati, V., Stohl, S., et al. Spine surgery and blood loss: Systematic review of Clinical evidence. Anesth Analg 123 (2016), 1307–1315.
48. Li, G., Sun, T.W., Luo, G., et al. Efficacy of antifibrinolytic agents on surgical bleeding and transfusion requirements in spine surgery: A meta-analysis. Eur Spine J 26 (2017), 140–154.
49. Soroceanu, A., Oren, J.H., Smith, J.S., et al. Effect of antifibrinolytic therapy on complications, thromboembolic events, blood product utilization, and fusion in adult spinal deformity surgery. Spine 41 (2016), E879–E886.
50. Wang, M., Zheng, X.F., Jiang, L.S., Efficacy and safety of antifibrinolytic agents in reducing perioperative blood loss and transfusion requirements in scoliosis surgery: A systematic review and meta-analysis. PLoS One, 10, 2015, e0137886.
51. Germans, M.R., Post, R., Coert, B.A., et al. Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): Study protocol for a randomized controlled trial. Trials, 14, 2013, 143.
52. Roos, Y., Rinkel, G., Vermeulen, M., et al. Antifibrinolytic therapy for aneurysmal subarachnoid hemorrhage: A major update of a Cochrane review. Stroke 34 (2003), 2308–2309.
53. Baharoglu, M.I., Germans, M.R., Rinkel, G.J., et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev, 2013, CD:001245.
54. Connolly, E.S. Jr, Rabinstein, A.A., Carhuapoma, J.R., et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 43 (2012), 1711–1737.
55. Diringer, M.N., Bleck, T.P., Claude Hemphill, J. 3rd, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: Recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocrit Care 15 (2011), 211–240.
56. Netherlands Trial Register. Ultra-early tranexamic acid after subarachnoid hemorrhage. Available at: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=3272. Accessed January 8, 2017.
57. Molenaar, I.Q., Warnaar, N., Groen, H., et al. Efficacy and safety of antifibrinolytic drugs in liver transplantation: A systematic review and meta-analysis. Am J Transplant 7 (2007), 185–194.
58. Mangus, R.S., Kinsella, S.B., Fridell, J.A., et al. Aminocaproic Acid (amicar) as an alternative to aprotinin (trasylol) in liver transplantation. Transplant Proc 46 (2014), 1393–1399.
59. Nicolau-Raducu, R., Ku, T.C., Ganier, D.R., et al. Epsilon-aminocaproic acid has no association with thromboembolic complications, renal failure, or nortality after liver transplantation. J Cardiothorac Vasc Anesth 30 (2016), 917–923.
60. Ker, K., Roberts, I., Shakur, H., et al. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Re, 2015 CD:004896.
61. Rossaint, R., Bouillon, B., Cerny, V., et al. The European guideline on management of major bleeding and coagulopathy following trauma: Fourth edition. Crit Care, 20, 2016, 100.
62. Sucher, M.G., Giordani, M., Figoni, A., et al. Peri-operative blood-loss after total hip arthroplasty can be significantly reduced with topical application of epsilon-aminocaproic acid. Int Orthop 40 (2016), 2019–2023.
63. Gurian, D.B., Meneghini, A., Abreu, L.C., et al. A randomized trial of the topical effect of antifibrinolytic epsilon aminocaproic acid on coronary artery bypass surgery without cardiopulmonary bypass. Clin Appl Thromb Hemost 20 (2014), 615–620.
64. Bennett-Guerrero, E., Sorohan, J.G., Canada, A.T., et al. epsilon-Aminocaproic acid plasma levels during cardiopulmonary bypass. Anesth Analg 85 (1997), 248–251.
65. Butterworth, J., James, R.L., Lin, Y.A., et al. Gender does not influence epsilon-aminocaproic acid concentrations in adults undergoing cardiopulmonary bypass. Anesth Analg 92 (2001), 1384–1390.
66. Lundell, J.C., Evidence-based EACA dosing?. Anesth Analg, 94, 2002, 1673 author reply 1673.
67. Greilich, P.E., Brouse, C.F., Whitten, C.W., et al. Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: A randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin. J Thorac Cardiovasc Surg 126 (2003), 1498–1503.
68. Hodgson, S., Larvin, J.T., Dearman, C., What dose of tranexamic acid is most effective and safe for adult patients undergoing cardiac surgery?. Interact Cardiov Th 21 (2015), 384–388.
69. Sharma, V., Fan, J., Jerath, A., et al. Pharmacokinetics of tranexamic acid in patients undergoing cardiac surgery with use of cardiopulmonary bypass. Anaesthesia 67 (2012), 1242–1250.
70. Yang, Q.J., Jerath, A., Bies, R.R., et al. Pharmacokinetic modeling of tranexamic acid for patients undergoing cardiac surgery with normal renal function and model simulations for patients with renal impairment. Biopharm Drug Dispos 36 (2015), 294–307.
71. Ririe, D.G., James, R.L., O'Brien, J.J., et al. The pharmacokinetics of epsilon-aminocaproic acid in children undergoing surgical repair of congenital heart defects. Anesth Analg 94 (2002), 44–49.
72. Sarupria, A., Makhija, N., Lakshmy, R., et al. Comparison of different doses of epsilon-aminocaproic acid in children for tetralogy of Fallot surgery: Clinical efficacy and safety. J Cardiothorac Vasc Anesth 27 (2013), 23–29.
73. Grassin-Delyle, S., Couturier, R., Abe, E., et al. A practical tranexamic acid dosing scheme based on population pharmacokinetics in children undergoing cardiac surgery. Anesthesiology 118 (2013), 853–862.
74. Stricker, P.A., Gastonguay, M.R., Singh, D., et al. Population pharmacokinetics of ε-aminocaproic acid in adolescents undergoing posterior spinal fusion surgery. Br J Anaesth 114 (2015), 689–699.
75. Wei, Z., Liu, M., The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: A meta-analysis of 2720 cases. Transfus Med 25 (2015), 151–162.
76. Malekpour, M., Kulwin, C., Bohnstedt, B.N., et al. Effect of short-term epsilon-aminocaproic acid treatment on patients undergoing endovascular coil embolization following aneurysmal subarachnoid hemorrhage. J Neurosurg, 2016 June 17 [Epub ahead of print].
77. CRASH-2 Trial Collaborators, Shakur, H., Roberts, I., et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebo-controlled trial. Lancet 376 (2010), 23–32.
78. Morrison, J.J., Dubose, J.J., Rasmussen, T.E., et al. Military application of tranexamic acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg 147 (2012), 113–119.
79. Morrison, J.J., Ross, J.D., Dubose, J.J., et al. Association of cryoprecipitate and tranexamic acid with improved survival following wartime injury: Findings from the MATTERs II Study. JAMA Surg 148 (2013), 218–225.
80. Eckert, M.J., Wertin, T.M., Tyner, S.D., et al. Tranexamic acid administration to pediatric trauma patients in a combat setting: The pediatric trauma and tranexamic acid study (PED-TRAX). J Trauma Acute Care Surg 77 (2014), 852–858.
81. Ker, K., Shakur, H., Roberts, I., Does tranexamic acid prevent postpartum haemorrhage? A systematic review of randomised controlled trials. BJOG 123 (2016), 1745–1752.
82. Goobie, S.M., Meier, P.M., Pereira, L.M., et al. Efficacy of tranexamic acid in pediatric craniosynostosis surgery: A double-blind, placebo-controlled trial. Anesthesiology 114 (2011), 862–871.
83. Kluger, R., Olive, D.J., Stewart, A.B., et al. Epsilon-aminocaproic acid in coronary artery bypass graft surgery: Preincision or postheparin?. Anesthesiology 99 (2003), 1263–1269.
84. McCormack, P.L., Tranexamic acid: A review of its use in the treatment of hyperfibrinolysis. Drugs 72 (2012), 585–617.
85. Dietrich, W., Spath, P., Ebell, A., et al. Prevalence of anaphylactic reactions to aprotinin: Analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiov Sur 113 (1997), 194–201.
86. European Society of Anaesthesiology Task Force Reports on Place of Aprotinin in Clinical Anesthesia. Aprotinin: Is it time to reconsider?. Eur J Anaesthesiol 32 (2015), 591–595.
87. Ma, S.C.A., Brindle, W., Burton, G., et al. Tranexamic acid is associated with less blood transfusion in off-pump coronary artery bypass graft surgery: A systematic review and meta-analysis. J Cardiothor Vasc Anesth 25 (2011), 26–35.
88. Krivokuca, I., Lammers, J.W., Recurrent pulmonary embolism associated with a hemostatic drug: Tranexamic acid. Clin Appl Thromb Hemost 17 (2011), 106–107.
89. Goldhaber, S.Z., Risk factors for venous thromboembolism. J Am Coll Cardiol 56 (2010), 1–7.
90. Nilsson, I.M., Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl 14 (1980), 41–47.
91. Salam, A., King, C., Orhan, O., et al. The great deception: Tranexamic acid and extensive pulmonary emboli. BMJ Case Rep, 2013, 2013.
92. Bruce-Brand, R., Dragomir, R., Baker, J., et al. Cerebrovascular infarction following bilateral total knee arthroplasty and tranexamic acid administration. Acta Orthop Belg 79 (2013), 351–354.
93. Ng, W., Jerath, A., Wasowicz, M., Tranexamic acid: A clinical review. Anaesthesiol Intensive Ther 47 (2015), 339–350.
94. Parsons, M.R., Merritt, D.R., Ramsay, R.C., Retinal artery occlusion associated with tranexamic acid therapy. Am J Ophthalmol 105 (1988), 688–689.
95. Gerstein, N.S., Brierley, J.K., Culling, M.D., Left ventricle thrombus after tranexamic acid for spine surgery in an HIV-positive patient. Spine J 16 (2016), e77–e82.
96. Royston, D., Aprotinin versus lysine analogues: The debate continues. Ann Thorac Surg 65 (1998), S9–19 discussion S27–8.
97. Perazella, M.A., Biswas, P., Acute hyperkalemia associated with intravenous epsilon-aminocaproic acid therapy. Am J Kidney Dis 33 (1999), 782–785.
98. Banerjee, A., Stoica, C., Walia, A., Acute hyperkalemia as a complication of intravenous therapy with epsilon-aminocaproic acid. J Clin Anesth 23 (2011), 565–568.
99. Seymour, B.D., Rubinger, M., Rhabdomyolysis induced by epsilon-aminocaproic acid. Ann Pharmacother 31 (1997), 56–58.
100. Ekeh, A.P., Dominguez, K.M., Markert, R.J., et al. Incidence and risk factors for deep venous thrombosis after moderate and severe brain injury. J Trauma 68 (2010), 912–915.
101. Chwajol, M., Starke, R.M., Kim, G.H., et al. Antifibrinolytic therapy to prevent early rebleeding after subarachnoid hemorrhage. Neurocrit Care 8 (2008), 418–426.
102. Myles, P.S., Smith, J.A., Forbes, A., et al. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med 376 (2017), 136–148.
103. Lin, Z., Xiaoyi, Z., Tranexamic acid-associated seizures: A meta-analysis. Seizure 36 (2016), 70–73.
104. Xia, V.W., Steadman, R.H., Antifibrinolytics in orthotopic liver transplantation: Current status and controversies. Liver Transpl 11 (2005), 10–18.
105. Drugs.com. Aminocaproic acid pregnancy and breastfeeding warnings. Available at: https://www.drugs.com/pregnancy/aminocaproic-acid.html. Accessed Novemeber 5, 2016.
106. Cravens, G.T., Brown, M.J., Brown, D.R., et al. Antifibrinolytic therapy use to mitigate blood loss during staged complex major spine surgery: Postoperative visual color changes after tranexamic acid administration. Anesthesiology 105 (2006), 1274–1276.
107. Fanashawe, M.P., Shore-Lesserson, L., Reich, D.L., Two cases of fatal thrombosis after aminocaproic acid therapy and deep hypothermic circulatory arrest. Anesthesiology 95 (2001), 1525–1527.
108. Aprile, A.E., Palmer, T.J., The intraoperative use of Amicar to reduce bleeding associated with open heart surgery. AANA J 63 (1995), 325–331.
109. Achiron, A., Gornish, M., Melamed, E., Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia. Stroke 21 (1990), 817–819.
110. Low YMC, Terrando N, Berger M, et al. Aminocaproic acid is associated with decreased cognition early after cardiac surgery compared to tranexamic acid. Abstract #JS03. Presented at 2016 American Society of Annual Meeting, Chicago, IL.
111. Mutter, W.P., Stillman, I.E., Dahl, N.K., Thrombotic microangiopathy and renal failure exacerbated by epsilon-aminocaproic acid. Am J Kidney Dis 53 (2009), 346–350.
112. Manjunath, G., Fozailoff, A., Mitcheson, D., et al. Epsilon-aminocaproic acid and renal complications: Case report and review of the literature. Clin Nephrol 58 (2002), 63–67.
113. Hutton, B., Joseph, L., Fergusson, D., et al. Risks of harms using antifibrinolytics in cardiac surgery: Systematic review and network meta-analysis of randomised and observational studies. Brit Med J, 345, 2012, e5798.
114. Morris, C.D., Jacobs, P., Berman, P.A., et al. Epsilon-aminocaproic acid-induced myopathy. A case report. S Afr Med J 64 (1983), 363–366.
115. Galassi, G., Gibertoni, M., Corradini, L., et al. Why may epsilon-aminocaproic acid (EACA) induce myopathy in man? Report of a case and literature review. Ital J Neurol Sci 4 (1983), 489–492.
116. Vanneste, J.A., van Wijngaarden, G.K., Epsilon-aminocaproic acid myopathy. Report of a case and literature review. Eur Neurol 21 (1982), 242–248.
117. Foreman, P.M., Chua, M., Harrigan, M.R., et al. Antifibrinolytic therapy in aneurysmal subarachnoid hemorrhage increases the risk for deep venous thrombosis: A case-control study. Clin Neurol Neurosurg 139 (2015), 66–69.
118. Grizelj, R., Vukovic, J., Filipovic-Grcic, B., et al. Successful use of recombinant activated FVII and aminocaproic acid in four neonates with life-threatening hemorrhage. Blood Coagul Fibrinolysis 17 (2006), 413–415.
119. Lee AT, Barnes CR, Jain S, et al. High dose, prolonged epsilon aminocaproic acid infusion, and recombinant factor VII for massive postoperative retroperitoneal hemorrhage following splenectomy. Case Rep Anesthesiol 2016;2016:1630385.
120. Centers for Disease Control and Prevention. Neonatals death associated with use of benzyl alcohol—United States. Available at: https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm. Accessed January 5, 2017.
121. Okamoto, S., Sato, S., Takada, Y., et al. An active stereo-isomer (trans-form) of Amcha and its antifibrinolytic (antiplasminic) action in vitro and in vivo. Keio J Med 13 (1964), 177–185.
122. Binz, S., McCollester, J., Thomas, S., et al. CRASH-2 study of tranexamic acid to treat bleeding in trauma patients: A controversy fueled by science and social media. J Blood Transfus, 2015, 2015, 874920.
123. Brown, R.S., Thwaites, B.K., Mongan, P.D., Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: A double-blind, randomized, placebo-controlled trial. Anesth Analg 85 (1997), 963–970.
124. Horrow, J.C., Hlavacek, J., Strong, M.D., et al. Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg 99 (1990), 70–74.
125. Cesarman-Maus, G., Hajjar, K.A., Molecular mechanisms of fibrinolysis. Br J Haematol 129 (2005), 307–321.
126. Hoylaerts, M., Lijnen, H.R., Collen, D., Studies on the mechanism of the antifibrinolytic action of tranexamic acid. Biochim Biophys Acta 673 (1981), 75–85.
127. Nadeau, R.P., Howard, J.L., Naudie, D.D., Antifibrinolytic therapy for perioperative blood conservation in lower-extremity primary total joint arthroplasty. JBJS Rev, 2015, 3.
128. Andersson, L., Eriksson, O., Hedlund, P.O., et al. Special considerations with regard to the dosage of tranexamic acid in patients with chronic renal diseases. Urol Res 6 (1978), 83–88.
129. Horrow, J.C., Van Riper, D.F., Strong, M.D., et al. The dose-response relationship of tranexamic acid. Anesthesiology 82 (1995), 383–392.
130. Fiechtner, B.K., Nuttall, G.A., Johnson, M.E., et al. Plasma tranexamic acid concentrations during cardiopulmonary bypass. Anesth Analg 92 (2001), 1131–1136.
131. Nuttall, G.A., Gutierrez, M.C., Dewey, J.D., et al. A preliminary study of a new tranexamic acid dosing schedule for cardiac surgery. J Cardiothorac Vasc Anesth 22 (2008), 230–235.
132. Gilad, O., Merlob, P., Stahl, B., et al. Outcome following tranexamic acid exposure during breastfeeding. Breastfeed Med 9 (2014), 407–410.
133. Dowd, N.P., Karski, J.M., Cheng, D.C., et al. Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology 97 (2002), 390–399.
134. Ker, K., Edwards, P., Perel, P., et al. Effect of tranexamic acid on surgical bleeding: Systematic review and cumulative meta-analysis. Brit Med J, 344, 2012, e3054.
135. Casati, V., Gerli, C., Franco, A., et al. Tranexamic acid in off-pump coronary surgery: A preliminary, randomized, double-blind, placebo-controlled study. Ann Thorac Surg 72 (2001), 470–475.
136. Jares, M., Vanek, T., Straka, Z., et al. Tranexamic acid reduces bleeding after off-pump coronary artery bypass grafting. J Cardiovasc Surg 44 (2003), 205–208.
137. Wei, M., Jian, K., Guo, Z., et al. Tranexamic acid reduces postoperative bleeding in off-pump coronary artery bypass grafting. Scand Cardiovasc J 40 (2006), 105–109.
138. Casati, V., Della Valle, P., Benussi, S., et al. Effects of tranexamic acid on postoperative bleeding and related hematochemical variables in coronary surgery: Comparison between on-pump and off-pump techniques. J Thorac Cardiovasc Surg 128 (2004), 83–91.
139. Vanek, T., Jares, M., Fajt, R., et al. Fibrinolytic inhibitors in off-pump coronary surgery: A prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo). Eur J Cardiothorac Surg 28 (2005), 563–568.
140. Taghaddomi, R.J., Mirzaee, A., Attar, A.S., et al. Tranexamic acid reduces blood loss in off-pump coronary artery bypass surgery. J Cardiothorac Vasc Anesth 23 (2009), 312–315.
141. Wang, G., Xie, G., Jiang, T., et al. Tranexamic acid reduces blood loss after off-pump coronary surgery: A prospective, randomized, double-blind, placebo-controlled study. Anesth Analg 115 (2012), 239–243.
142. Menkis, A.H., Martin, J., Cheng, D.C., et al. Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: A consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011. Innovations 7 (2012), 229–241.
143. Ker, K., Kiriya, J., Perel, P., et al. Avoidable mortality from giving tranexamic acid to bleeding trauma patients: An estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial. BMC Emerg Med, 12, 2012, 3.
144. Yu, X., Li, W., Xu, P., et al. Safety and efficacy of tranexamic acid in total knee arthroplasty. Med Sci Monit 21 (2015), 3095–3103.
145. Farrow, L.S., Smith, T.O., Ashcroft, G.P., et al. A systematic review of tranexamic acid in hip fracture surgery. Br J Clin Pharmacol 82 (2016), 1548–1570.
146. Li, Z.J., Fu, X., Xing, D., et al. Is tranexamic acid effective and safe in spinal surgery? A meta-analysis of randomized controlled trials. Eur Spine J 22 (2013), 1950–1957.
147. Cheriyan, T., Maier, S.P., Bianco, K., et al. Efficacy of tranexamic acid on surgical bleeding in spine surgery: A meta-analysis. Spine J 15 (2015), 752–761.
148. Shakur, H., Elbourne, D., Gulmezoglu, M., et al. The WOMAN Trial (World Maternal Antifibrinolytic Trial): Tranexamic acid for the treatment of postpartum haemorrhage: An international randomised, double blind placebo controlled trial. Trials, 11, 2010, 40.
149. London School of Hygiene and Tropical Medicine. Woman World Maternal Antifibrinolytic Trial. Available at: http://womantrial.lshtm.ac.uk/. Accessed January 8, 2017.
150. Aguilera, X., Martinez-Zapata, M., Hinarejos, P., et al. Topical and intravenous tranexamic acid reduce blood loss compared to routine hemostasis in total knee arthroplasty: A multicenter, randomized, controlled trial. Arch Orthop Traum Surg 135 (2015), 1017–1025.
151. Li, J., Zhang, Z.J., Chen, J., Comparison of efficacy and safety of topical versus intravenous tranexamic acid in total hip arthroplasty: A meta-analysis. Medicine (Baltimore), 95, 2016, e4689.
152. North, W.T., Mehran, N., Davis, J.J., et al. Topical vs intravenous tranexamic acid in primary total hip arthroplasty: A double-blind, randomized controlled trial. J Arthroplasty 31 (2016), 1022–1026.
153. Hallstrom, B., Singal, B., Cowen, M.E., et al. The Michigan experience with safety and effectiveness of tranexamic acid use in hip and knee arthroplasty. J Bone Joint Surg Am 98 (2016), 1646–1655.
154. Ogawa, S., Richardson, J.E., Sakai, T., et al. High mortality associated with intracardiac and intrapulmonary thromboses after cardiopulmonary bypass. J Anesth 26 (2012), 9–19.
155. Spanyer, J., Patel, J., Emberton, E., et al. Topical tranexamic acid in total knee arthroplasty patients with increased thromboembolic risk. J Knee Surg, 2016 Oct 5 [Epub ahead of print].
156. Manji, R.A., Grocott, H.P., Leake, J., et al. Seizures following cardiac surgery: The impact of tranexamic acid and other risk factors. Can J Anaesth 59 (2012), 6–13.
157. Lecker, I., Wang, D.S., Whissell, P.D., et al. Tranexamic acid-associated seizures: Causes and treatment. Ann Neurol 79 (2016), 18–26.
158. Martin, K., Wiesner, G., Breuer, T., et al. The risks of aprotinin and tranexamic acid in cardiac surgery: A one-year follow-up of 1188 consecutive patients. Anesth Analg 107 (2008), 1783–1790.
159. Hunt, B.J., The current place of tranexamic acid in the management of bleeding. Anaesthesia 70:Suppl 1 (2015), 50–53 e18.
160. Brouwer, M.E., McMeniman, W.J., Seizures following cardiopulmonary bypass. J Extra Corpor Technol 48 (2016), 137–140.
161. Kalavrouziotis, D., Voisine, P., Mohammadi, S., et al. High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. Ann Thorac Surg 93 (2013), 148–155.
162. Sigaut, S., Tremey, B., Ouattara, A., et al. Comparison of two doses of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. Anesthesiology 120 (2014), 590–600.
163. Singh, L.M., Howard, J.M., Studies of trasylol. Evaluation of trasylol against the hypotensive effects of trypsin and kallikrein. Arch Surg 91 (1965), 635–639.
164. Prentice, C.R., Basis of antifibrinolytic therapy. J Clin Pathol Suppl 14 (1980), 35–40.
165. Fritz, H., Wunderer, G., Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung 33 (1983), 479–494.
166. Segal, H., Hunt, B.J., Aprotinin: Pharmacological reduction of perioperative bleeding. Lancet 355 (2000), 1289–1290.
167. Nixon, A.E., Wood, C.R., Engineered protein inhibitors of proteases. Curr Opin Drug Discov Devel 9 (2006), 261–268.
168. Westaby, S., Aprotinin: Twenty-five years of claim and counterclaim. J Thorac Cardiovasc Surg 135 (2008), 487–491.
169. Royston, D., Bidstrup, B.P., Taylor, K.M., et al. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 2 (1987), 1289–1291.
170. Smith, C.R., Management of bleeding complications in redo cardiac operations. Ann Thorac Surg 65 (1998), S2–S8 discussion S27–8.
171. Samama, C.M., Langeron, O., Rosencher, N., et al. Aprotinin versus placebo in major orthopedic surgery: A randomized, double-blinded, dose-ranging study. Anesth Analg 95 (2002), 287–293.
172. Fergusson, D., Glass, K.C., Hutton, B., et al. Randomized controlled trials of aprotinin in cardiac surgery: Could clinical equipoise have stopped the bleeding?. Clin Trials 2 (2005), 218–232.
173. Karkouti, K., Beattie, W.S., Dattilo, K.M., et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 46 (2006), 327–338.
174. Furnary, A.P., Wu, Y., Hiratzka, L.F., et al. Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation 116 (2007), I127–I133.
175. Mangano, D.T., Miao, Y., Vuylsteke, A., et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 297 (2007), 471–479.
176. DeSantis, S.M., Toole, J.M., Kratz, J.M., et al. Early postoperative outcomes and blood product utilization in adult cardiac surgery: The post-aprotinin era. Circulation 124 (2011), S62–S69.
177. Deanda, A. Jr, Spiess, B.D., Aprotinin revisited. J Thorac Cardiovasc Surg 144 (2012), 998–1002.
178. Vande Vusse, L.K., Zacharski, L.R., Dumas, M.G., et al. Prohemostatic therapy: The rise and fall of aprotinin. Semin Thromb Hemost 36 (2010), 103–112.
179. McMullan, V., Alston, R.P., III. Aprotinin and cardiac surgery: A sorry tale of evidence misused. Br J Anaesth 110 (2013), 675–678.
180. Health Canada. Final report-expert panel advisory on Trasylol (aprotinin). Available at: http://hc-sc.gc.ca/dhp-mps/medeff/advise-consult/eap-gce_trasylol/final_rep-rap-eng.php. Accessed September 20, 2016.
181. European Medicines Agency, Science Medicines Health. European Medicines Agency recommends lifting suspension on aprotinin. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/02/WC500122914.pdf. Accessed September 17, 2016.
182. Government of Canada. Recalls and safety alerts: Trasylol (aprotinin) – important safety information – for the public. Available at: http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/14107a-eng.php. Accessed November 5, 2016.
183. Nordic Group. European Commission approved reinstatement of aprotinin/Trasylol marketing authorisations in European Union. Available at: http://www.prnewswire.co.uk/news-releases/european-commission-approved-reinstatement-of-aprotinintrasylol-marketing-authorisations-in-european-union-227205591.html. Accessed November 5, 2016.
184. Hebert, P.C., Fergusson, D.A., Hutton, B., et al. Regulatory decisions pertaining to aprotinin may be putting patients at risk. CMAJ 186 (2014), 1379–1386.
185. Karkouti, K., Wijeysundera, D.N., Yau, T.M., et al. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg 110 (2010), 21–29.
186. Sander, M., Spies, C.D., Martiny, V., et al. Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: A retrospective analysis. Crit Care, 14, 2010, R148.
187. Nishijima, D.K., Monuteaux, M.C., Faraoni, D., et al. Tranexamic acid use in United States children's hospitals. J Emerg Med, 50(868–74), 2016, e1.
188. Pasquali, S.K., Hall, M., Li, J.S., et al. Safety of aprotinin in congenital heart operations: Results from a large multicenter database. Ann Thorac Surg 90 (2010), 14–21.
189. Pasquali, S.K., Li, J.S., He, X., et al. Comparative analysis of antifibrinolytic medications in pediatric heart surgery. J Thorac Cardiov Sur 143 (2012), 550–557.
190. Graham, E.M., Atz, A.M., Gillis, J., et al. Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery. J Thorac Cardiovasc Surg 143 (2012), 1069–1076.
191. Schouten, E.S., van de Pol, A.C., Schouten, A.N., et al. The effect of aprotinin, tranexamic acid, and aminocaproic acid on blood loss and use of blood products in major pediatric surgery: A meta-analysis. Pediatr Crit Care Med 10 (2009), 182–190.
192. Scott, J.P., Costigan, D.J., Hoffman, G.M., et al. Increased recombinant activated factor VII use and need for surgical reexploration following a switch from aprotinin to epsilon-aminocaproic acid in infant cardiac surgery. J Clin Anesth 26 (2014), 204–211.
193. Shimizu, K., Toda, Y., Iwasaki, T., et al. Effect of tranexamic acid on blood loss in pediatric cardiac surgery: A randomized trial. J Anesth 25 (2011), 823–830.
194. Giordano, R., Palma, G., Poli, V., et al. Tranexamic acid therapy in pediatric cardiac surgery: A single-center study. Ann Thorac Surg 94 (2012), 1302–1306.
195. Lu, J., Meng, H., Meng, Z., et al. Epsilon aminocaproic acid reduces blood transfusion and improves the coagulation test after pediatric open-heart surgery: A meta-analysis of 5 clinical trials. Int J Clin Exp Pathol 8 (2015), 7978–7987.
196. Martin, K., Breuer, T., Gertler, R., et al. Tranexamic acid versus varepsilon-aminocaproic acid: Efficacy and safety in paediatric cardiac surgery. Eur J Cardiothorac Surg 39 (2011), 892–897.
197. Breuer, T., Martin, K., Wilhelm, M., et al. The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery. Eur J Cardiothorac Surg 35 (2009), 167–171 author reply 171.
198. Naim, M.Y., Gaynor, J.W., Chen, J., et al. Subclinical seizures identified by postoperative electroencephalographic monitoring are common after neonatal cardiac surgery. J Thorac Cardiovasc Surg 150 (2015), 169–180.
199. Gaynor, J.W., Jarvik, G.P., Gerdes, M., et al. Postoperative electroencephalographic seizures are associated with deficits in executive function and social behaviors at 4 years of age following cardiac surgery in infancy. J Thorac Cardiovasc Surg 146 (2013), 132–137.
200. Kajimoto, H., Nakazawa, M., Murasaki, K., et al. Increased thrombogenesity in patients with cyanotic congenital heart disease. Circ J 71 (2007), 948–953.
201. Ravn, H.B., Hjortdal, V.E., Stenbog, E.V., et al. Increased platelet reactivity and significant changes in coagulation markers after cavopulmonary connection. Heart 85 (2001), 61–65.
202. Lykissas, M.G., Crawford, A.H., Chan, G., et al. The effect of tranexamic acid in blood loss and transfusion volume in adolescent idiopathic scoliosis surgery: A single-surgeon experience. J Child Orthop 7 (2013), 245–249.
203. Newton, P.O., Bastrom, T.P., Emans, J.B., et al. Antifibrinolytic agents reduce blood loss during pediatric vertebral column resection procedures. Spine 37 (2012), E1459–E1463.
204. McLeod, L.M., French, B., Flynn, J.M., et al. Antifibrinolytic use and blood transfusions in pediatric scoliosis surgeries performed at US children's hospitals. J Spinal Disord Tech 28 (2015), E460–E466.
205. Goobie, S.M., Zurakowski, D., Proctor, M.R., et al. Predictors of clinically significant postoperative events after open craniosynostosis surgery. Anesthesiology 122 (2015), 1021–1032.
206. Crantford, J.C., Wood, B.C., Claiborne, J.R., et al. Evaluating the safety and efficacy of tranexamic acid administration in pediatric cranial vault reconstruction. J Craniofac Surg 26 (2015), 104–107.
207. Hsu, G., Taylor, J.A., Fiadjoe, J.E., et al. Aminocaproic acid administration is associated with reduced perioperative blood loss and transfusion in pediatric craniofacial surgery. Acta Anaesthesiol Scand 60 (2016), 158–165.
208. Martin, D.T., Gries, H., Esmonde, N., et al. Implementation of a tranexamic acid protocol to reduce blood loss during cranial vault remodeling for craniosynostosis. J Craniofac Surg 27 (2016), 1527–1531.
209. Song, G., Yang, P., Zhu, S., et al. Tranexamic acid reducing blood transfusion in children undergoing craniosynostosis surgery. J Craniofac Surg 24 (2013), 299–303.
210. Basta, M.N., Stricker, P.A., Taylor, J.A., A systematic review of the use of antifibrinolytic agents in pediatric surgery and implications for craniofacial use. Pediatr Surg Int 28 (2012), 1059–1069.
211. CRASH-2 Collaborators, Roberts, I., Shakur, H., et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: An exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 377 (2011), 1096–1101 1101.e1–2.
212. Phan, D.L., Ani, F., Schwarzkopf, R., Cost analysis of tranexamic acid in anemic total joint arthroplasty patients. J Arthroplasty 31 (2016), 579–582.
213. Lin, Z.L.X., Woolf, S.K., Safety, efficacy, and cost-effectiveness of tranexamic acid in orthopedic surgery. Orthopedics 39 (2016), 119–130.
214. Yan, C.H., Commentary: Clinical and financial benefits of intra-articular tranexamic acid in total knee arthroplasty. J Orthop Surg (Hong Kong), 24, 2016, 2.
215. Roberts, I., Coats, T., Edwards, P., et al. HALT-IT—tranexamic acid for the treatment of gastrointestinal bleeding: Study protocol for a randomised controlled trial. Trials, 15, 2014, 450.
216. Dewan, Y., Komolafe, E.O., Mejia-Mantilla, J.H., et al. CRASH-3—tranexamic acid for the treatment of significant traumatic brain injury: Study protocol for an international randomized, double-blind, placebo-controlled trial. Trials, 13, 2012, 87.
217. Bokesch, P.M., Szabo, G., Wojdyga, R., et al. A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial). J Thorac Cardiovasc Surg 143 (2012), 1022–1029.
218. Reust, D.L., Reeves, S.T., Abernathy, J.H., et al. Interstitial plasmin activity with epsilon aminocaproic acid: Temporal and regional heterogeneity. Ann Thorac Surg 89 (2010), 1538–1545.
219. Englberger, L., Dietrich, W., Eberle, B., et al. A novel blood-sparing agent in cardiac surgery? First in-patient experience with the synthetic serine protease inhibitor MDCO-2010: A phase II, randomized, double-blind, placebo-controlled study in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Anesth Analg 119 (2014), 16–25.
220. Koster, A., Faraoni, D., Levy, J.H., Antifibrinolytic therapy for cardiac surgery: An update. Anesthesiology 123 (2015), 214–221.
221. Baylis, J.R., Yeon, J.H., Thomson, M.H., et al. Self-propelled particles that transport cargo through flowing blood and halt hemorrhage. Sci Adv, 1, 2015, e1500379.
222. Sarda, S., Errassifi, F., Marsan, O., et al. Adsorption of tranexamic acid on hydroxyapatite: Toward the development of biomaterials with local hemostatic activity. Mater Sci Eng C Mater Biol Appl 66 (2016), 1–7.
223. U.S. Food and Drug Administration. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm142720.htm. Accessed December 15, 2016.
224. Yuan, C., Zhang, H., He, S., Efficacy and safety of using antifibrinolytic agents in spine surgery: A meta-analysis. PLoS One, 8, 2013, e82063.
225. Levy, J.H., Hemostatic agents. Transfusion 44 (2004), 58S–62S.
226. Moskal, J.T., Capps, S.G., Meta-analysis of intravenous tranexamic acid in primary total hip arthroplasty. Orthopedics 39 (2016), e883–e892.
227. Zufferey, P., Merquiol, F., Laporte, S., et al. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?. Anesthesiology 105 (2006), 1034–1046.
228. Berenholtz, S.M., Pham, J.C., Garrett-Mayer, E., et al. Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery. Spine 34 (2009), 2096–2103.
229. Berman, M., Cardone, D., Sharples, L., et al. Safety and efficacy of aprotinin and tranexamic acid in pulmonary endarterectomy surgery with hypothermia: Review of 200 patients. Ann Thorac Surg 90 (2010), 1432–1436.
230. Mihalache, R.M., Ames, P.R., Deep vein thrombosis, tranexamic acid, and a negative d-dimer. Clin Appl Thromb Hemost 18 (2012), 666–667.